NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECHNIVIE is a fixed-dose combination oral tablet containing ombitasvir, paritaprevir, and ritonavir, developed by AbbVie for the treatment of chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) regimen that inhibits HCV NS5A, NS3/4A protease, and utilizes ritonavir as a pharmacokinetic booster. The combination targets patients with HCV genotype 4 infection, offering an all-oral, interferon-free treatment option.
Peak5.8 years to LOE
Product is at peak commercial maturity with established market presence; brand teams are focused on market maintenance and optimization rather than launch-phase expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECHNIVIE offers exposure to a mature, peak-stage commercial product in a specialty care setting with established prescriber relationships and market dynamics. However, with zero linked job openings and LOE approaching in 5.8 years, career growth is constrained; roles are maintenance-focused rather than growth-oriented, and team size is likely stable or contracting.
Brand Manager
Worked on TECHNIVIE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.